Top Suppliers and Manufacturers of Raw Materials in China 🇨🇳

China National Pharmaceutical Group Corporation, widely known as Sinopharm, is a major player in the global pharmaceutical industry. Established in 1998, the company has its headquarters in Beijing, China. Sinopharm specializes in the research, development, manufacturing, and distribution of pharmaceutical products, including a wide range of biopharmaceuticals, anaesthetics, psychotropics, anti-infectives, anti-tumor medications, and cardiovascular drugs.

Sinopharm is recognized for its top products, which include vaccines, therapeutic drugs, and medical devices. The company has played a significant role in global healthcare, especially noted for its contribution to the global supply of COVID-19 vaccines. It maintains a strong international presence, exporting products to over 80 countries worldwide, including regions such as North America, Europe, Southeast Asia, Africa, and the Middle East.

With a robust distribution network and a commitment to innovation, Sinopharm ensures high-quality healthcare products reach healthcare providers and patients efficiently. The company actively participates in international health initiatives and maintains partnerships that enhance its global footprint. As of 2023, Sinopharm reported revenues of US$ 96.1 billion and employs approximately 202,426 individuals, making it one of the largest pharmaceutical enterprises in China.

Sinopharm's extensive history is marked by growth and expansion in both domestic and international markets. The company has established itself as a reliable and innovative leader in the pharmaceutical field through its continuous investments in research and development. Leveraging government support and market opportunities, Sinopharm remains dedicated to improving health outcomes globally.

Baiyunshan Pharmaceutical Holdings is a prominent player in China's pharmaceutical industry, renowned for its extensive range of both traditional Chinese and Western medicines, along with a variety of healthcare products. The company's offerings are organized into several key segments, including Great Southern TCM, which focuses on research, development, manufacturing, and sales of medicinal products, and Great Health, which emphasizes the development and sales of health products, beverages, and foods.

Specializing in the pharmaceutical and healthcare sectors, Baiyunshan stands out for its focus on traditional Chinese medicine (TCM) alongside modern healthcare solutions. Its Great Commerce segment handles the wholesale and retail of medical apparatus, instruments, and traditional as well as Western medicines, supported by active import and export operations. The Great Medical Care segment provides comprehensive medical services and modern healthcare solutions, reinforcing the company's commitment to health and wellness.

Founded in 1997 and headquartered in Guangzhou, one of China's key economic regions, Baiyunshan has grown significantly over the years. The company has established a substantial international presence with export markets spanning Europe, Southeast Asia, and North America, cementing its reputation as a leader in the pharmaceutical sector. By leveraging both traditional practices and modern scientific advancements, Baiyunshan continues to innovate within the industry.

In 2024, Baiyunshan reported impressive revenues of CNY 76.83 billion and maintained a robust workforce of 28,050 employees. This growth trajectory demonstrates the company's ability to meet global healthcare needs while maintaining high standards of quality and safety. Baiyunshan Pharmaceutical Holdings remains committed to promoting health and well-being globally, ensuring its products meet the highest international compliance requirements.

Sinopharm Group, also known as China National Pharmaceutical Group Corporation, is a state-owned enterprise based in China and a leading player in the global pharmaceutical and biotechnology industries. Established in 1998, with its headquarters in Beijing, Sinopharm has developed a robust infrastructure in pharmaceutical research, development, manufacturing, and distribution.

The company's top products include a wide range of vaccines and pharmaceutical drugs, among other healthcare products. Sinopharm has notably contributed to global health through its development and distribution of various vaccines, including the Sinopharm BIBP COVID-19 vaccine, utilized during the pandemic.

Sinopharm's extensive operations include three main business segments:

• Pharmaceutical Distribution: This segment provides logistics and value-added supply chain services for both domestic and international healthcare manufacturers.
• Retail Pharmacy: The company operates a widespread network of retail drug stores across major cities in China, comprising both directly operated and franchised outlets.
• Other Operations: This segment involves the production and sale of medical devices, chemical reagents, laboratory supplies, as well as financial leasing services.

Sinopharm's significant presence extends to export markets in Asia, Africa, Europe, and the Americas, underscoring its role in global healthcare initiatives. In 2023, the company reported a remarkable revenue of US$96.1 billion, supporting its status as a powerhouse in the industry. With a workforce of over 202,426 employees, Sinopharm continues to enhance public health by delivering high-quality medical products and services.

As the largest distributor of pharmaceutical and healthcare products in China, Sinopharm is renowned for its extensive logistics network, allowing for efficient distribution of healthcare supplies to various regions. This commitment to innovation and quality has solidified its reputation as an essential contributor to the healthcare sector worldwide.

Shanghai Fosun Pharmaceutical Group, widely known as Fosun Pharma, is a leading player in the global healthcare sector. Founded in 1994 and headquartered in Shanghai, China, the company excels in the research, development, manufacturing, and distribution of pharmaceutical products. Specializing in sectors such as oncology, immunomodulation, cardiovascular and central nervous system disorder treatments, Fosun Pharma has built an extensive portfolio of innovative drugs, mature pharmaceutical products, and medical devices.

Fosun Pharma's dedication to innovation has led to the development of groundbreaking technologies including RNA-based therapies, oncolytic viruses, and gene therapy. The company operates internationally, with a strong presence in over 30 countries across Asia, Europe, and the Americas, establishing itself as a major exporter of pharmaceutical products and healthcare solutions.

Throughout its history, the company has prioritized patient-centered care and meeting clinical needs. It has collaborated with various international R&D teams and formed numerous partnerships and joint ventures to expand its market reach and capabilities. Notable acquisitions, such as a major stake in Gland Pharma, have further strengthened its position in the industry.

Fosun Pharma's business is structured across several key areas: pharmaceutical manufacturing and R&D, healthcare services, medical devices, and pharmaceutical distribution. In 2022, the company reported a revenue of approximately $4.7 billion, reflecting its significant market presence and operational capacity. Employing around 20,000 individuals as of 2023, Fosun Pharma continues to lead the way in delivering high-quality healthcare solutions globally.

Hunan Er-Kang Pharmaceutical is a prominent player in the pharmaceutical industry, specializing in the research, development, production, and sale of various pharmaceutical products. Founded in October 2003 and headquartered in Changsha, Hunan, the company has established itself as the largest manufacturer of pharmaceutical excipients in China. It offers a comprehensive range of products, including pharmaceutical excipients, active pharmaceutical ingredients (APIs), and finished dosage forms.

The company's top products include 100% vegetarian starch capsules (StarchCaps), starch for softgel shells (StarchGel), glycerol, medicinal alcohol, propylene glycol, and medicinal sodium hydroxide. Er-Kang is also known for its high-quality bulk drugs like sulfadiazine, sulphaguanidine, and resorcinol, as well as finished drugs such as sulbenicillin sodium injections and compound liquorice tablets.

Hunan Er-Kang Pharmaceutical serves a global client base, with its products being essential components in various formulations. The firm exports to multiple international markets, reflecting its commitment to extending its reach beyond domestic operations. This international presence is further bolstered by the company's participation in major events like Vitafoods Europe, showcasing its capabilities to a global audience.

Committed to quality and innovation, Hunan Er-Kang invests significantly in research and development, utilizing proprietary technologies to maintain its competitive edge. The company's dedication to safety and environmental sustainability is encapsulated in its principle that 'Drug Safety Is Above Everything.'

Located in the Liuyang Bio-Medical Industrial Park, the company benefits from the region's rich resources and skilled workforce. With an employee base exceeding 10,001, Hunan Er-Kang continues to lead advancements in pharmaceutical science, providing high-quality healthcare solutions both domestically and internationally.